Immunotherapy Combinations for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests new combinations of immunotherapy drugs for advanced cancers that cannot be surgically removed or have spread. It evaluates the safety and effectiveness of these drug combinations against cancer. The trial includes two groups, each testing a different drug mix: one with relatlimab, nivolumab, and BMS-986205 (an experimental treatment), and the other with relatlimab, nivolumab, and ipilimumab. Individuals with certain advanced cancers who have tried other treatments or have not yet tried immunotherapy might be suitable candidates. As a Phase 1, Phase 2 trial, this research focuses on understanding how the treatment works in people and measuring its effectiveness in an initial, smaller group.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that combining the drugs relatlimab and nivolumab is generally safe and does not cause unexpected problems. Their safety profile is similar to when each drug is used individually.
In another study, combining nivolumab with ipilimumab was linked to various side effects, particularly those affecting the immune system, such as skin changes or inflammation in different body parts. However, adding relatlimab to this combination might increase the risk of heart-related issues.
These findings clarify the potential side effects of these drug combinations. Prospective trial participants should discuss any concerns with their healthcare provider.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments because they combine cutting-edge immunotherapies to tackle cancer in novel ways. Relatlimab, a new addition, targets the LAG-3 protein on immune cells, potentially enhancing the immune response against cancer. Meanwhile, Nivolumab and Ipilimumab are well-known for targeting PD-1 and CTLA-4 pathways, respectively, which are crucial in immune checkpoint blockade. By combining these treatments, the approach aims to boost the immune system more effectively than current options, like traditional chemotherapy or monotherapy immunotherapies, offering hope for better outcomes in cancer treatment.
What evidence suggests that this trial's treatments could be effective for cancer?
This trial will evaluate the effectiveness of different immunotherapy combinations for cancer. Participants in Arm A will receive a combination of Relatlimab, Nivolumab, and BMS-986205. Studies have shown that using Relatlimab with Nivolumab can help treat advanced cancers, with patients experiencing stable disease for twice as long compared to standard treatments.
Participants in Arm B will receive Relatlimab, Nivolumab, and Ipilimumab. The combination of Nivolumab and Ipilimumab has improved survival rates more than Ipilimumab alone. Research suggests that these drugs, when used together, can help the immune system better find and fight cancer cells. Overall, these combinations show promising results in improving outcomes for patients with various advanced cancers.13467Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for adults with certain advanced solid cancers that have spread and can't be removed by surgery. Participants should be relatively healthy (ECOG status of 0 or 1) and have a tumor that can be measured. They must also provide tissue samples for research. People with brain metastases, lung inflammation history, active cancer in the last two years (except some skin cancers), or recent serious neurological issues cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a combination of relatlimab, nivolumab, and either BMS-986205 or ipilimumab to assess safety and preliminary activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BMS-986205
- Ipilimumab
- Nivolumab
- Relatlimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania